379 related articles for article (PubMed ID: 35818539)
1. Cardiovascular Disease in Myeloproliferative Neoplasms:
Leiva O; Hobbs G; Ravid K; Libby P
JACC CardioOncol; 2022 Jun; 4(2):166-182. PubMed ID: 35818539
[TBL] [Abstract][Full Text] [Related]
2. Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer.
Barbui T; Gavazzi A; Sciatti E; Finazzi MC; Ghirardi A; Carioli G; Carobbio A
Curr Hematol Malig Rep; 2023 Aug; 18(4):105-112. PubMed ID: 37221411
[TBL] [Abstract][Full Text] [Related]
3. Clonal Hematopoiesis: A New Step Linking Inflammation to Heart Failure.
Yura Y; Sano S; Walsh K
JACC Basic Transl Sci; 2020 Feb; 5(2):196-207. PubMed ID: 32140625
[TBL] [Abstract][Full Text] [Related]
4. Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.
Loscocco GG; Coltro G; Guglielmelli P; Vannucchi AM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440731
[TBL] [Abstract][Full Text] [Related]
5. Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?
Fulvio G; Baldini C; Mosca M; di Paolo A; Bocci G; Palumbo GA; Cacciola E; Migliorini P; Cacciola R; Galimberti S
Front Med (Lausanne); 2023; 10():1254868. PubMed ID: 37915324
[TBL] [Abstract][Full Text] [Related]
6. Genetics of Myeloproliferative Neoplasms.
Szybinski J; Meyer SC
Hematol Oncol Clin North Am; 2021 Apr; 35(2):217-236. PubMed ID: 33641865
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
Haybar H; Khodadi E; Shahjahani M; Saki N
Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
[TBL] [Abstract][Full Text] [Related]
8. Functional Consequences of Mutations in Myeloproliferative Neoplasms.
Constantinescu SN; Vainchenker W; Levy G; Papadopoulos N
Hemasphere; 2021 Jun; 5(6):e578. PubMed ID: 34095761
[TBL] [Abstract][Full Text] [Related]
9. Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation.
Perner F; Perner C; Ernst T; Heidel FH
Cells; 2019 Aug; 8(8):. PubMed ID: 31398915
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
11.
Sano S; Wang Y; Yura Y; Sano M; Oshima K; Yang Y; Katanasaka Y; Min KD; Matsuura S; Ravid K; Mohi G; Walsh K
JACC Basic Transl Sci; 2019 Oct; 4(6):684-697. PubMed ID: 31709318
[TBL] [Abstract][Full Text] [Related]
12. Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.
Calabresi L; Balliu M; Bartalucci N
Methods Cell Biol; 2022; 171():81-109. PubMed ID: 35953207
[TBL] [Abstract][Full Text] [Related]
13. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
Marin Oyarzún CP; Heller PG
Front Immunol; 2019; 10():1373. PubMed ID: 31258539
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
15. Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms.
Hinze A; Rinke J; Crodel CC; Möbius S; Schäfer V; Heidel FH; Hochhaus A; Ernst T
Br J Haematol; 2023 Jul; 202(2):308-317. PubMed ID: 37139709
[TBL] [Abstract][Full Text] [Related]
16. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
17. Age-Associated
Ferrone CK; Blydt-Hansen M; Rauh MJ
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963585
[TBL] [Abstract][Full Text] [Related]
18. Disease modifying agents of myeloproliferative neoplasms: a review.
Lee SE
Blood Res; 2021 Apr; 56(S1):S26-S33. PubMed ID: 33935032
[TBL] [Abstract][Full Text] [Related]
19. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
[TBL] [Abstract][Full Text] [Related]
20. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.
Jia R; Kralovics R
Int J Hematol; 2020 Feb; 111(2):182-191. PubMed ID: 31741139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
